(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(2.16%) $83.11
(1.98%) $1.752
(1.90%) $2 254.80
(1.41%) $25.10
(1.45%) $922.85
(0.36%) $0.927
(0.76%) $10.85
(0.10%) $0.792
(0.13%) $92.56
@ $215.09
Issued: 27 Mar 2024 @ 14:24
Return: 0.25%
Previous signal: Mar 27 - 13:42
Previous signal:
Return: 0.33 %
Live Chart Being Loaded With Signals
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis...
Stats | |
---|---|
Today's Volume | 1.76M |
Average Volume | 1.16M |
Market Cap | 31.34B |
EPS | $0 ( 2024-02-13 ) |
Next earnings date | ( $3.48 ) 2024-04-23 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 27.09 |
ATR14 | $3.54 (1.64%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-22 | Singhal Priya | Sell | 262 | Common Stock |
2024-02-16 | Alexander Susan H | Buy | 3 423 | Common Stock |
2024-02-16 | Alexander Susan H | Buy | 1 614 | Common Stock |
2024-02-16 | Alexander Susan H | Sell | 781 | Common Stock |
2024-02-16 | Alexander Susan H | Sell | 1 656 | Common Stock |
INSIDER POWER |
---|
7.53 |
Last 100 transactions |
Buy: 88 430 | Sell: 75 725 |
Volume Correlation
Biogen Inc Correlation
10 Most Positive Correlations | |
---|---|
EVCM | 0.883 |
RBNC | 0.879 |
NLTX | 0.879 |
ACLX | 0.878 |
EGRX | 0.873 |
ARCT | 0.865 |
HBIO | 0.863 |
NATI | 0.862 |
FCFS | 0.861 |
MDLZ | 0.858 |
10 Most Negative Correlations | |
---|---|
NYMTN | -0.908 |
WTRE | -0.908 |
RNMC | -0.903 |
REIT | -0.903 |
KBWD | -0.9 |
SDVY | -0.899 |
NEOG | -0.899 |
FFBW | -0.898 |
XT | -0.895 |
ICHR | -0.895 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Biogen Inc Correlation - Currency/Commodity
Biogen Inc Financials
Annual | 2023 |
Revenue: | $9.84B |
Gross Profit: | $7.30B (74.24 %) |
EPS: | $8.02 |
Q4 | 2023 |
Revenue: | $2.39B |
Gross Profit: | $1.77B (74.09 %) |
EPS: | $1.720 |
Q3 | 2023 |
Revenue: | $2.53B |
Gross Profit: | $1.87B (73.93 %) |
EPS: | $-0.470 |
Q2 | 2023 |
Revenue: | $2.46B |
Gross Profit: | $1.86B (75.87 %) |
EPS: | $4.09 |
Financial Reports:
No articles found.
Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators